DegludecPlus insulin degludec/insulin aspart regulatory update

Novo Nordisk said FDA accepted for review an NDA for DegludecPlus to treat Type I and II diabetes. The PDUFA date is July 29. DegludecPlus is a combination of 70% insulin Degludec, a long-acting insul...